Technology
Health
Biotechnology

Genetic Technologies

$0.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (1.10%) Today
+$0.01 (1.10%) Today

Why Robinhood?

You can buy or sell GENE and other stocks, options, ETFs, and crypto commission-free!

About

Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Read More Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Employees
Headquarters
Fitzroy, Victoria (VIC)
Founded
1987
Market Cap
16.04M
Price-Earnings Ratio
Dividend Yield
Average Volume
173.32K
High Today
$0.94
Low Today
$0.9071
Open Price
$0.94
Volume
6.11K
52 Week High
$2.04
52 Week Low
$0.512

Collections

Technology
Health
Biotechnology
Cancer Prevention

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.